Biophysical comparability of the same protein from different manufacturers: A case study using Epoetin alfa from Epogen® and Eprex®

Journal of Pharmaceutical Sciences

Volumn 95, Issue 9, 2006, Pages 1931-1943

  Deechongkit, Songpon ^a   Aoki, Kenneth H ^a   Park, Sungae S ^a   Kerwin, Bruce A ^a  

^a AMGEN INC   (United States)

Author keywords

Analytical ultra centrifugation; Circular dichroism; Comparability; Epoetin alfa; Erythropoietin; Fluorescence spectroscopy; Glycoprotein; Protein conformation; Protein folding refolding; UV Vis spectroscopy

Indexed keywords

CARBOHYDRATE; GLYCAN; RECOMBINANT ERYTHROPOIETIN; SIALIC ACID;

ALPHA HELIX; ANEMIA; ANION EXCHANGE CHROMATOGRAPHY; ARTICLE; CARBOHYDRATE ANALYSIS; CIRCULAR DICHROISM; COMPARATIVE STUDY; DRUG CONFORMATION; DRUG FORMULATION; DRUG INDUSTRY; FLUORESCENCE MICROSCOPY; HYDRODYNAMICS; MOLECULAR WEIGHT; PROTEIN ANALYSIS; PROTEIN FOLDING; PROTEIN SECONDARY STRUCTURE; PROTEIN STRUCTURE; SEDIMENTATION RATE; TEMPERATURE ACCLIMATIZATION; ULTRACENTRIFUGATION;

EID: 33748921915     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.20649     Document Type: Article

References (36)

1. Chirino AJ, Mire-Sluis A. 2004. Characterizing biological products and assessing comparability following manufacturing changes. Nat Biotechnol 22:1383-1391.
2. Lai PH, Everett R, Wang FF, Arakawa T, Goldwasser E. 1985. Structural characterization of human erythropoietin. J Biol Chem 261:3116-3121.
3. Takeuchi M, Takasaki S, Miyazaki H, Kato T, Hoshi S, Kochibe N, Kobata A. 1988. Comparative study of the asparagine-linked sugar chains of human erythropoietins purified from urine and the culture medium of recombinant Chinese hamster ovary cells. J Biol Chem 263:3657-3663.
4. Imai N, Kawamura A, Higuchi M, Oh-eda M, Orita T, Kawaguchi T, Ochi N. 1990. Physicochemical and biological comparison of recombinant human erythropoietin with human urinary erythropoietin. J Biochem 107:352-359.
5. Sasaki H, Bothner B, Dell A, Fukuda M. 1987. Carbohydrate structure of erythropoietin expressed in Chinese hamster ovary cells by a human erythropoietin cDNA. J Biol Chem 262:12059-12076.
6. Jelkmann W, Metzen E. 1996. Erythropoietin in the control of red cell production. Ann Anat 178:391-403.
7. Israels LG, Israels ED. 2003. Erythropoiesis: An overview. In: Molineux G, Foote MA, Elliott SG, editors. Erythropoietins and erythropoiesis. milestones in drug therapy. Basel: Birkhauser, pp. 3-14.
8. Markham A, Bryson HM. 1995. Epoetin alfa: A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in nonrenal applications. Drugs 49:232-254.
9. Arakawa T, Philo JS. 2002. Biophysical and biochemical analysis of recombinant proteins: Structure and analysis of proteins. In: Crommelin DJA, Sindelar RD, editors. Pharmaceutical biotechnology. Philadelphia: Taylor and Francis Inc, pp. 25-52.
10. Plaxco KW, Dobson CM. 1996. Time-resolved biophysical methods in the study of protein folding. Curr Opin Struct Biol 6:630-636.
11. Cheetham JC, Smith DM, Aoki KH, Stevenson JL, Hoeffel TJ, Syed RS, Egrie J, Harvey TS. 1998. NMR structure of human erythropoietin and a comparison with its receptor bound conformation. Nat Struct Biol 5:861-866.
12. Lakowicz JR. 1999 Principles of Fluorescent Spectroscopy, 2nd Ed. New York: Kluwer Academic/Plenum Publishers.
13. Ricci MS, Brems DN. 2004. Common structural stability properties of 4-helical bundle cytokines: Possible physiological and pharmaceutical consequences. Curr Pharm Des 10:3901-3911.
14. Stafford WF, Schuster TM. 1995. Hydrodynamic transport methods. In: Glasel JA, Deutscher MP, editors. Introduction to biophysical methods for protein and nucleic acid research. Orlando: Academic Press, pp. 111-145.
15. Lebowitz J, Lewis MS, Schuck P. 2003. Back to the future: A rebuttal to Henryk Eisenberg. Protein Sci 12:2649-2650.
16. Consumer Medicine Information. http://www.med-safe.govt.nz/consumers/cmi/ e/Eprex.htm (Accessed November 29, 2004).
17. Lebowitz J, Lewis MS, Schuck P. 2002. Modern analytical ultracentrifugation in protein science: A tutorial review. Protein Sci 11:2067-2079.
18. Venyaminov SY, Yang JT. 1996. Determination of protein secondary structure. In: Fasman GD, editor. Circular dichroism and the conformational analysis of biomolecules. New York and London: Plenum press, pp 69-108.
19. Sinha A, Yadav S, Ahmad R, Ahmad F. 2000. A possible origin of differences between calorimetric and equilibrium estimates of stability parameters of proteins. Biochem J 345 Pt 3:711-717.
20. Gursky O, Atkinson D. 1998. Thermodynamic analysis of human plasma apolipoprotein C-1: High-temperature unfolding and low-temperature oligomer dissociation. Biochemistry 37:1283-1291.
21. Greenfield N, Fasman GD. 1969. Computed circular dichroism spectra for the evaluation of protein conformation. Biochemistry 8:4108-4116.
22. Russ WP, Ranganathan R. 2002. Knowledge-based potential functions in protein design. Curr Opin Struct Biol 12:447-452.
23. Anfinsen CB. 1973. Principles that govern the folding of protein chains. Science 181:223-230.
24. Fetrow JS, Giammona A, Kolinski A, Skolnick J. 2002. The protein folding problem: A biophysical enigma. Curr Pharm Biotechnol 3:329-347.
25. Fischer D, Rice D, Bowie JU, Eisenberg D. 1996. Assigning amino acid sequence to 3-dimensional protein folds. FASEB J 10:126-136.
26. Plaxco KW, Riddle DS, Grantcharova V, Baker D. 1998. Simplified proteins: Minimalist solutions to the 'protein folding problem'. Curr Opin Struct Biol 8:80-85.
27. Dill KA, Chan HS. 1997. From Levinthal to pathways to funnels. Nat Struct Biol 4:10-19.
28. Davis JM, Arakawa T, Strickland TW, Yphantis DA. 1987. Characterization of recombinant human erythropoietin produced in Chinese hamster ovary cells. Biochemistry 26:2633-2638.
29. Linsley KB, Chan SY, Chan S, Reinhold BB, Lisi PJ, Reinhold VN. 1994. Applications of electrospray mass spectrometry to erythropoietin N- and O-linked glycans. Anal Biochem 219:207-217.
30. Toyoda T, Itai T, Arakawa T, Aoki KH, Yamaguchi H. 2000. Stabilization of human recombinant erythropoietin through interactions with the highly branched N-glycans. J Biochem 128:731-737.
31. Locatelli F, Aljama P, Barany P, Canaud B, Carrera F, Eckardt KU, Macdougall IC, Macleod A, Horl WH, Wiecek A, Cameron S. 2004. Erythropoiesis-stimulating agents and antibody-mediated pure red-cell aplasia: Here are we now and where do we go from here? Nephrol Dial Transplant 19:288-293.
32. Casadevall N, Nataf J, Viron B, Kolta A, Kiladjian JJ, Martin-Dupont P, Michaud P, Papo T, Ugo V, Teyssandier I, Varet B, Mayeux P. 2002. Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin. N Engl J Med 346:469-475.
33. Macdougall IC. 2004. Pure red cell aplasia with anti-erythropoietin antibodies occurs more commonly with one formulation of epoetin alfa than another. Curr Med Res Opin 20:83-86.
34. Casadevall N. 2002. Antibodies against rHuEPO: Native and recombinant. Nephrol Dial Transplant 17:42-47.
35. European Medicines Agency: Committee for Medicinal Products for Human Use. 2005. Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: Quality Issues. Draft Guidelines: EMEA/CHMP/49348/05.
36. Villalobos AP, Gunturi SR, Heavner GA. 2005. Interaction of polysorbate 80 with erythropoietin: A Case Study in Protein-Surfactant Interactions. Pharm Res 22:1186-1194.